

Dirk Kuypers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/261463/publications.pdf>

Version: 2024-02-01

354
papers

18,563
citations

10373

72
h-index

19169

118
g-index

358
all docs

358
docs citations

358
times ranked

14365
citing authors

#	ARTICLE	IF	CITATIONS
1	Calcineurin Inhibitor Nephrotoxicity. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 481-508.	2.2	1,178
2	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. Therapeutic Drug Monitoring, 2009, 31, 139-152.	1.0	398
3	Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. Journal of Medical Genetics, 2004, 41, e84-e84.	1.5	311
4	Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation. Therapeutic Drug Monitoring, 2006, 28, 145-154.	1.0	305
5	Diagnosis and prevention of chronic kidney allograft loss. Lancet, The, 2011, 378, 1428-1437.	6.3	279
6	Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 341-358.	2.2	276
7	Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrology Dialysis Transplantation, 2004, 19, 1281-1287.	0.4	273
8	p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1182-1189.	2.2	265
9	MULTICENTER TRIAL EXPLORING CALCINEURIN INHIBITORS AVOIDANCE IN RENAL TRANSPLANTATION. Transplantation, 2001, 71, 1282-1287.	0.5	246
10	Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial. Transplantation, 2008, 86, 1043-1051.	0.5	238
11	EFFECT OF HISTOLOGICAL DAMAGE ON LONG-TERM KIDNEY TRANSPLANT OUTCOME. Transplantation, 2001, 71, 515-523.	0.5	236
12	Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biology, 2018, 68-69, 44-66.	1.5	230
13	Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients. Transplantation, 2017, 101, S1-S56.	0.5	217
14	Three-Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients. American Journal of Transplantation, 2005, 5, 2521-2530.	2.6	208
15	Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney International, 2004, 65, 1842-1849.	2.6	206
16	Improved Adherence to Tacrolimus Once-Daily Formulation in Renal Recipients. Transplantation, 2013, 95, 333-340.	0.5	203
17	Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. Kidney International, 2018, 94, 964-973.	2.6	198
18	CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal Recipients. Clinical Pharmacology and Therapeutics, 2007, 82, 711-725.	2.3	192

#	ARTICLE	IF	CITATIONS
19	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. <i>BMJ: British Medical Journal</i> , 2019, 366, 14923.	2.4	191
20	Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients. <i>Transplantation</i> , 2006, 82, 1074-1084.	0.5	187
21	Intrarenal Resistive Index after Renal Transplantation. <i>New England Journal of Medicine</i> , 2013, 369, 1797-1806.	13.9	185
22	The impact of uridine diphosphate-glucuronosyltransferase 1A9 () gene promoter region single-nucleotide polymorphisms and on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 351-361.	2.3	171
23	Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2009, 9, 1205-1213.	2.6	161
24	Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 434-447.	2.3	157
25	Adjuvant Low-Dose Cidofovir Therapy for BK Polyomavirus Interstitial Nephritis in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 1997-2004.	2.6	157
26	New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 416-435.	1.0	146
27	Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3479-3487.	3.0	144
28	Tertiary ?Hyperphosphatemia? Accentuates Hypophosphatemia and Suppresses Calcitriol Levels in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2007, 7, 1193-1200.	2.6	143
29	Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. <i>Transplantation</i> , 2003, 75, 665-672.	0.5	142
30	Twelve-Month Evaluation of the Clinical Pharmacokinetics of Total and Free Mycophenolic Acid and Its Glucuronide Metabolites in Renal Allograft Recipients on Low Dose Tacrolimus in Combination with Mycophenolate Mofetil. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 609-622.	1.0	134
31	POSTTRANSPLANTATION DIABETES MELLITUS IN FK-506-TREATED RENAL TRANSPLANT RECIPIENTS: ANALYSIS OF INCIDENCE AND RISK FACTORS. <i>Transplantation</i> , 2001, 72, 1655-1661.	0.5	128
32	Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2468-2480.	3.0	126
33	Recovery of Hyperphosphatemia and Renal Phosphorus Wasting One Year after Successful Renal Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1829-1836.	2.2	124
34	The Histology of Kidney Transplant Failure. <i>Transplantation</i> , 2014, 98, 427-435.	0.5	124
35	Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1714-1720.	0.4	123
36	Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. <i>Drug Metabolism Reviews</i> , 2016, 48, 88-112.	1.5	119

#	ARTICLE	IF	CITATIONS
37	Bartter's and Gitelman's Syndromes: From Gene to Clinic. <i>Nephron Physiology</i> , 2004, 96, p65-p78.	1.5	117
38	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. <i>Transplantation Reviews</i> , 2011, 25, 47-57.	1.2	116
39	The P450 oxidoreductase <i>CYP28</i> SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. <i>Pharmacogenomics</i> , 2011, 12, 1281-1291.	0.6	116
40	Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study. <i>American Journal of Transplantation</i> , 2016, 16, 3192-3201.	2.6	116
41	Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation. <i>Kidney International</i> , 2019, 95, 188-198.	2.6	116
42	UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 319-327.	2.3	112
43	PREDICTORS OF RENAL TRANSPLANT HISTOLOGY AT THREE MONTHS. <i>Transplantation</i> , 1999, 67, 1222-1230.	0.5	111
44	CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 339-348.	0.7	110
45	The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. <i>Kidney International</i> , 2014, 85, 636-640.	2.6	106
46	The Influence of CKD on Colonic Microbial Metabolism. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1389-1399.	3.0	106
47	Prometheus Versus Molecular Adsorbents Recirculating System: Comparison of Efficiency in Two Different Liver Detoxification Devices. <i>Artificial Organs</i> , 2006, 30, 276-284.	1.0	105
48	Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft Recipients. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 394-404.	1.0	103
49	Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. <i>Leukemia and Lymphoma</i> , 2013, 54, 2433-2440.	0.6	103
50	Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and Corticosteroids. <i>Clinical Pharmacokinetics</i> , 2004, 43, 741-762.	1.6	102
51	High Inpatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. <i>American Journal of Transplantation</i> , 2016, 16, 2954-2963.	2.6	102
52	Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome. <i>American Journal of Transplantation</i> , 2019, 19, 763-780.	2.6	102
53	Current target ranges of mycophenolic acid exposure and drug-related adverse events: A 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. <i>Clinical Therapeutics</i> , 2008, 30, 673-683.	1.1	100
54	In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 366-375.	2.3	100

#	ARTICLE	IF	CITATIONS
55	Long-Term Changes in Mycophenolic Acid Exposure in Combination with Tacrolimus and Corticosteroids Are Dose Dependent and Not Reflected by Trough Plasma Concentration: A Prospective Study in 100 De Novo Renal Allograft Recipients. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 866-880.	1.0	99
56	Management of polyomavirus-associated nephropathy in renal transplant recipients. <i>Nature Reviews Nephrology</i> , 2012, 8, 390-402.	4.1	98
57	Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2193-2204.	3.0	98
58	Parathyroidectomy after successful kidney transplantation: a single centre study. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1730-1737.	0.4	96
59	Fibroblast Growth Factor-23 in Early Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1268-1276.	2.2	96
60	Renal Clearance and Intestinal Generation of p-Cresyl Sulfate and Indoxyl Sulfate in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1508-1514.	2.2	93
61	Benefit-Risk Assessment of Sirolimus in Renal Transplantation. <i>Drug Safety</i> , 2005, 28, 153-181.	1.4	92
62	A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1895-1901.	0.4	83
63	The Predictive Value of Kidney Allograft Baseline Biopsies for Long-Term Graft Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1913-1923.	3.0	83
64	Detoxifying Capacity and Kinetics of Prometheus [®] – A New Extracorporeal System for the Treatment of Liver Failure. <i>Blood Purification</i> , 2005, 23, 349-358.	0.9	82
65	Tacrolimus Exposure and Evolution of Renal Allograft Histology in the First Year After Transplantation. <i>American Journal of Transplantation</i> , 2007, 7, 2114-2123.	2.6	82
66	The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2269-2276.	0.4	81
67	Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 71-79.	1.0	81
68	Inpatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 347-358.	2.3	80
69	Calcium Channel Blockade and Preservation of Renal Graft Function in Cyclosporine-Treated Recipients: A Prospective Randomized Placebo-Controlled 2-Year Study. <i>Transplantation</i> , 2004, 78, 1204-1211.	0.5	79
70	Skin problems in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2009, 5, 157-170.	4.1	77
71	The Influence of Dietary Protein Intake on Mammalian Tryptophan and Phenolic Metabolites. <i>PLoS ONE</i> , 2015, 10, e0140820.	1.1	77
72	Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study. <i>EBioMedicine</i> , 2019, 46, 463-472.	2.7	75

#	ARTICLE	IF	CITATIONS
73	The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial. PLoS ONE, 2016, 11, e0153893.	1.1	74
74	Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients. Clinical Pharmacology and Therapeutics, 2006, 80, 509-521.	2.3	73
75	Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenetics and Genomics, 2008, 18, 861-868.	0.7	72
76	Calcium Metabolism in the Early Posttransplantation Period. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 665-672.	2.2	72
77	Reduced CO Concentrations and Increased Dose Requirements in Renal Allograft Recipients Converted to the Novel Once-Daily Tacrolimus Formulation. Transplantation, 2010, 90, 523-529.	0.5	72
78	Drug interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphate-glucuronosyltransferase. Clinical Pharmacology and Therapeutics, 2005, 78, 81-88.	2.3	71
79	Effect of Cyclosporine Withdrawal on Mycophenolic Acid Pharmacokinetics in Kidney Transplant Recipients With Deteriorating Renal Function: Preliminary Report. Therapeutic Drug Monitoring, 2001, 23, 717-721.	1.0	70
80	Subclinical Peritubular Capillaritis at 3 Months Is Associated With Chronic Rejection at 1 Year. Transplantation, 2007, 83, 1416-1422.	0.5	70
81	An Assessment of Herpesvirus Co-infections in Patients with CMV Disease: Correlation with Clinical and Virologic Outcomes. American Journal of Transplantation, 2009, 9, 374-381.	2.6	70
82	Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrology Dialysis Transplantation, 2004, 19, 469-473.	0.4	69
83	The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder. Haematologica, 2013, 98, 771-775.	1.7	69
84	Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. Transplantation, 2019, 103, 1953-1963.	0.5	69
85	Heparin-Coated Polyacrylonitrile Membrane Versus Regional Citrate Anticoagulation: A Prospective Randomized Study of 2 Anticoagulation Strategies in Patients at Risk of Bleeding. American Journal of Kidney Diseases, 2007, 49, 642-649.	2.1	68
86	Immunotherapy in Elderly Transplant Recipients. Drugs and Aging, 2009, 26, 715-737.	1.3	68
87	FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α -synuclein-based rat model for Parkinson's disease. Neurobiology of Aging, 2015, 36, 1559-1568.	1.5	68
88	Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. American Journal of Transplantation, 2017, 17, 1853-1867.	2.6	68
89	Kidney Fibrosis. Transplantation, 2017, 101, 713-726.	0.5	67
90	A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. Journal of the American Society of Nephrology: JASN, 2019, 30, 1481-1494.	3.0	67

#	ARTICLE	IF	CITATIONS
91	Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. <i>Transplantation Reviews</i> , 2011, 25, 78-89.	1.2	66
92	Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3100-3113.	2.6	66
93	Plasma Concentrations of Mycophenolic Acid Acyl Glucuronide Are Not Associated with Diarrhea in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2007, 7, 1822-1831.	2.6	65
94	Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2033-2042.	0.4	65
95	European Society for Organ Transplantation Advisory Committee Recommendations on Generic Substitution of Immunosuppressive Drugs. <i>Transplant International</i> , 2011, 24, 1135-1141.	0.8	65
96	Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. <i>Transplantation Reviews</i> , 2011, 25, 58-64.	1.2	65
97	Factors influencing technical success and outcome of percutaneous balloon angioplasty in de novo native hemodialysis arteriovenous fistulas. <i>European Journal of Radiology</i> , 2012, 81, 2298-2303.	1.2	65
98	Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 281-292.	3.0	65
99	From gut to kidney: Transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. <i>International Journal of Pharmaceutics</i> , 2013, 452, 14-35.	2.6	63
100	Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. <i>Kidney International</i> , 2019, 95, 1461-1470.	2.6	61
101	Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. <i>American Journal of Kidney Diseases</i> , 2002, 39, 315-323.	2.1	60
102	Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome. <i>Transplant International</i> , 2005, 18, 140-150.	0.8	60
103	Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 2372-2380.	2.6	60
104	Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2168-2183.	3.0	60
105	Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1525-1533.	2.2	59
106	Differential Effect of Diarrhea on FK506 Versus Cyclosporine A Trough Levels and Resultant Prevention of Allograft Rejection in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2002, 2, 989-992.	2.6	58
107	Criteria for HNF1B analysis in patients with congenital abnormalities of kidney and urinary tract. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 835-842.	0.4	57
108	Metabolism, Protein Binding, and Renal Clearance of Microbiota-Derived p-Cresol in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1136-1144.	2.2	57

#	ARTICLE	IF	CITATIONS
109	Pharmacogenetics in solid organ transplantation: current status and future directions. <i>Transplantation Reviews</i> , 2008, 22, 6-20.	1.2	56
110	Chronic Histological Damage in Early Indication Biopsies Is an Independent Risk Factor for Late Renal Allograft Failure. <i>American Journal of Transplantation</i> , 2013, 13, 86-99.	2.6	56
111	Renal cortical nephrocalcinosis. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 1080-1082.	0.4	54
112	The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. <i>Clinical Transplantation</i> , 2003, 17, 234-241.	0.8	54
113	The value of tuberculin skin testing in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 433-438.	0.4	54
114	Clinical importance of extended second field high-resolution HLA genotyping for kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 3367-3378.	2.6	54
115	The Impact of Renal Allograft Function on Exposure and Elimination of Mycophenolic Acid (MPA) and Its Metabolite MPA 7-O-glucuronide. <i>Transplantation</i> , 2007, 84, 362-373.	0.5	52
116	Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. <i>Kidney International</i> , 2015, 87, 210-216.	2.6	52
117	Calcium Requirements after Parathyroidectomy in Patients with Refractory Secondary Hyperparathyroidism. <i>Nephron Clinical Practice</i> , 2008, 110, c80-c85.	2.3	51
118	Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. <i>Transplant International</i> , 2013, 26, 813-821.	0.8	51
119	Can antibody prophylaxis allow sparing of other immunosuppressives?. <i>Transplantation Proceedings</i> , 1999, 31, 1246-1248.	0.3	50
120	Genome-Wide Association Study of Acute Renal Graft Rejection. <i>American Journal of Transplantation</i> , 2017, 17, 201-209.	2.6	50
121	DIFFERENCES IN GASTRIC MOTOR ACTIVITY IN RENAL TRANSPLANT RECIPIENTS TREATED WITH FK-506 VERSUS CYCLOSPORINE. <i>Transplantation</i> , 1999, 68, 1482-1485.	0.5	50
122	Renal Transplant Patients at High Risk of Acute Rejection Benefit From Adequate Exposure to Mycophenolic Acid. <i>Transplantation</i> , 2010, 89, 595-599.	0.5	48
123	Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2014, 15, 87.	0.8	48
124	Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 548-559.	1.1	48
125	C3D DEPOSITION IN PERITUBULAR CAPILLARIES INDICATES A VARIANT OF ACUTE RENAL ALLOGRAFT REJECTION CHARACTERIZED BY A WORSE CLINICAL OUTCOME. <i>Transplantation</i> , 2003, 76, 102-108.	0.5	47
126	Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 1726-1734.	2.6	47

#	ARTICLE	IF	CITATIONS
127	Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. <i>American Journal of Kidney Diseases</i> , 2004, 43, e24.1-e24.5.	2.1	46
128	Localization, Etiology and Impact of Calcium Phosphate Deposits in Renal Allografts. <i>American Journal of Transplantation</i> , 2009, 9, 2470-2478.	2.6	46
129	The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. <i>Pharmacogenomics Journal</i> , 2015, 15, 144-152.	0.9	46
130	Detoxifying Capacity and Kinetics of the Molecular Adsorbent Recycling System. <i>Blood Purification</i> , 2003, 21, 244-252.	0.9	44
131	Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 597-606.	0.7	44
132	The Effect of Anastomosis Time on Outcome in Recipients of Kidneys Donated After Brain Death: A Cohort Study. <i>American Journal of Transplantation</i> , 2015, 15, 2900-2907.	2.6	43
133	Acute rejection in non-compliant renal allograft recipients: a distinct morphology. <i>Clinical Transplantation</i> , 2007, 21, 344-351.	0.8	41
134	Cutaneous phaeohyphomycosis in renal allograft recipients: report of 2 cases and review of the literature. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 177-180.	0.8	41
135	Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies. <i>Transplantation</i> , 2017, 101, 1924-1934.	0.5	41
136	AcylMPAG Plasma Concentrations and Mycophenolic Acid-Related Side Effects in Patients Undergoing Renal Transplantation Are Not Related to the UGT2B7-840G>A Gene Polymorphism. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 439-444.	1.0	40
137	Mycophenolic Acid Exposure after Administration of Mycophenolate Mofetil in the Presence and Absence of Ciclosporin in Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 329-341.	1.6	40
138	A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. <i>Clinical Therapeutics</i> , 2010, 32, 2012-2023.	1.1	40
139	Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 397-409.	3.0	40
140	A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 923-926.	0.4	38
141	Recurrence of glomerulonephritis after renal transplantation. <i>Transplantation Reviews</i> , 2013, 27, 126-134.	1.2	38
142	Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results. <i>American Journal of Transplantation</i> , 2013, 13, 1746-1756.	2.6	38
143	Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. <i>Kidney International</i> , 2014, 85, 1434-1443.	2.6	38
144	Invasive Aspergillosis After Kidney Transplant: Case-Control Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 1505-1511.	2.9	38

#	ARTICLE	IF	CITATIONS
145	Missing Self-Induced Microvascular Rejection of Kidney Allografts: A Population-Based Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2070-2082.	3.0	38
146	Expression of CYP3A5 and P-glycoprotein in Renal Allografts With Histological Signs of Calcineurin Inhibitor Nephrotoxicity. <i>Transplantation</i> , 2011, 91, 1098-1102.	0.5	37
147	Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. <i>Transplantation Reviews</i> , 2017, 31, 69-77.	1.2	37
148	Posttransplant Epstein-Barr Virus-Associated Myogenic Tumors: Case Report and Review of the Literature. <i>American Journal of Transplantation</i> , 2008, 8, 253-258.	2.6	36
149	In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine-Treated as Compared With Tacrolimus-Treated Renal Allograft Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 414-422.	2.3	36
150	Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. <i>Clinical Transplantation</i> , 2012, 26, 393-402.	0.8	36
151	Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients. <i>Transplant International</i> , 2013, 26, 973-981.	0.8	36
152	High Rate of Charcot Foot Attacks Early After Simultaneous Pancreas-Kidney Transplantation. <i>Transplantation</i> , 2007, 83, 245-246.	0.5	35
153	The influence of renal transplantation on retained microbial-human co-metabolites. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1721-1729.	0.4	35
154	Effect of the Direct Oral Anticoagulants Rivaroxaban and Apixaban on the Disposition of Calcineurin Inhibitors in Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 77-82.	1.0	35
155	Assessing the Complex Causes of Kidney Allograft Loss. <i>Transplantation</i> , 2020, 104, 2557-2566.	0.5	35
156	Fungal infections in solid organ transplantation: An update on diagnosis and treatment. <i>Transplantation Reviews</i> , 2019, 33, 77-86.	1.2	34
157	Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 2413-2423.	2.6	34
158	Hypotrichosis, lymphedema, telangiectasia, renal defect associated with a truncating mutation in the <i>SOX18</i> gene. <i>Clinical Genetics</i> , 2015, 87, 378-382.	1.0	33
159	Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology. <i>Clinica Chimica Acta</i> , 2008, 389, 87-92.	0.5	32
160	Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1508-1514.	0.4	32
161	Stenosis Detection in Native Hemodialysis Fistulas with MDCT Angiography. <i>American Journal of Roentgenology</i> , 2009, 192, 1079-1084.	1.0	31
162	Impact of <i>CYP3A5</i> genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in <i>CYP3A5</i> -mediated drug metabolism. <i>Pharmacogenomics</i> , 2013, 14, 1467-1480.	0.6	31

#	ARTICLE	IF	CITATIONS
163	Antibodies Against ARHGDI1 and ARHGDI1 Gene Expression Associate With Kidney Allograft Outcome. <i>Transplantation</i> , 2020, 104, 1462-1471.	0.5	31
164	Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. <i>American Journal of Kidney Diseases</i> , 2005, 45, e33-e37.	2.1	30
165	Donor-specific antibodies require preactivated immune system to harm renal transplant. <i>EBioMedicine</i> , 2016, 9, 366-371.	2.7	30
166	Another devastating complication of the Schnitzler syndrome: AA amyloidosis. <i>British Journal of Dermatology</i> , 2007, 158, 071018053044006-???	1.4	29
167	A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 417-419.	1.3	29
168	Tacrolimus-Induced Neutropenia in Renal Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 690-694.	2.2	29
169	Technology Experience of Solid Organ Transplant Patients and Their Overall Willingness to Use Interactive Health Technology. <i>Journal of Nursing Scholarship</i> , 2018, 50, 151-162.	1.1	29
170	THE RATE OF GASTRIC EMPTYING DETERMINES THE TIMING BUT NOT THE EXTENT OF ORAL TACROLIMUS ABSORPTION: SIMULTANEOUS MEASUREMENT OF DRUG EXPOSURE AND GASTRIC EMPTYING BY CARBON-14-OCTANOIC ACID BREATH TEST IN STABLE RENAL ALLOGRAFT RECIPIENTS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1421-1425.	1.7	28
171	The Functional Implications of Common Genetic Variation in <i>CYP3A5</i> and <i>ABCB1</i> in Human Proximal Tubule Cells. <i>Molecular Pharmaceutics</i> , 2015, 12, 758-768.	2.3	28
172	Data-driven Derivation and Validation of Novel Phenotypes for Acute Kidney Transplant Rejection using Semi-supervised Clustering. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1084-1096.	3.0	28
173	Limited cutaneous systemic sclerosis associated with MPO-ANCA positive renal small vessel vasculitis of the microscopic polyangiitis type. <i>American Journal of Kidney Diseases</i> , 2000, 36, e16.1-e16.5.	2.1	27
174	A Prospective, Randomized, Double-Blind Crossover Study on the Use of 5% Citrate Lock versus 10% Citrate Lock in Permanent Hemodialysis Catheters. <i>Blood Purification</i> , 2005, 23, 101-105.	0.9	27
175	Immunosuppression: Does One Regimen Fit All?. <i>Transplantation</i> , 2011, 92, 251-261.	0.5	27
176	Histological characteristics of Acute Tubular Injury during Delayed Graft Function predict renal function after renal transplantation. <i>Physiological Reports</i> , 2019, 7, e14000.	0.7	26
177	“Full house” positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2258-2262.	0.4	25
178	Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy. <i>American Journal of Kidney Diseases</i> , 2022, 79, 667-676.e1.	2.1	25
179	Renal transplantation onto abnormal urinary tract: ileal conduit urinary diversion. <i>Transplantation Proceedings</i> , 2001, 33, 2493-2494.	0.3	24
180	Combined 'En Bloc' Liver and Pancreas Transplantation in Patients with Liver Disease and Type 1 Diabetes Mellitus. <i>American Journal of Transplantation</i> , 2004, 4, 1921-1927.	2.6	24

#	ARTICLE	IF	CITATIONS
181	Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab?. <i>Transplant International</i> , 2007, 20, 381-385.	0.8	24
182	Comparative performance of oral midazolam clearance and plasma 4 β -hydroxycholesterol to explain interindividual variability in tacrolimus clearance. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1539-1549.	1.1	24
183	Measuring Total Blood Calcium Displays a Low Sensitivity for the Diagnosis of Hypercalcemia in Incident Renal Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2085-2092.	2.2	23
184	Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report. <i>Transplantation Reviews</i> , 2011, 25, 65-77.	1.2	23
185	Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: a multicenter study. <i>Transplant International</i> , 2012, 25, 391-400.	0.8	23
186	Kidney donation after circulatory death in a country with a high number of brain dead donors: 10-year experience in Belgium. <i>Transplant International</i> , 2012, 25, 857-866.	0.8	23
187	From Nonadherence to Adherence. <i>Transplantation</i> , 2020, 104, 1330-1340.	0.5	23
188	Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial. <i>Clinical Transplantation</i> , 2005, 19, 475-482.	0.8	22
189	Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 541-547.	1.1	22
190	The Once-Daily Formulation of Tacrolimus. <i>Transplantation</i> , 2012, 93, 241-243.	0.5	22
191	Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 399-407.	0.7	22
192	Resolution of diffuse skin and systemic Kaposi's sarcoma in a renal transplant recipient after introduction of everolimus: a case report. <i>Transplant Infectious Disease</i> , 2015, 17, 303-307.	0.7	22
193	The clinical significance of epitope mismatch load in kidney transplantation: A multicentre study. <i>Transplant Immunology</i> , 2018, 50, 55-59.	0.6	22
194	IgA antiglomerular basement membrane disease associated with bronchial carcinoma and monoclonal gammopathy. <i>American Journal of Kidney Diseases</i> , 1999, 33, e3.1-e3.5.	2.1	21
195	Drug Interaction Between Itraconazole and Sirolimus in a Primary Renal Allograft Recipient. <i>Transplantation</i> , 2005, 79, 737.	0.5	21
196	Clinically Relevant Drug Interaction Between Voriconazole and Tacrolimus in a Primary Renal Allograft Recipient. <i>Transplantation</i> , 2006, 81, 1750-1752.	0.5	21
197	Anticoagulation With Fondaparinux for Hemodiafiltration in Patients With Heparin-Induced Thrombocytopenia: Dose-Finding Study and Safety Evaluation. <i>Artificial Organs</i> , 2013, 37, 482-487.	1.0	21
198	Telomere length, cardiovascular risk and arteriosclerosis in human kidneys: an observational cohort study. <i>Aging</i> , 2015, 7, 766-775.	1.4	21

#	ARTICLE	IF	CITATIONS
199	Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism. <i>Transplantation</i> , 2016, 100, 2188-2193.	0.5	21
200	Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 697-705.	0.4	21
201	Long-Term Pharmacokinetic Study of the Novel Combination of Tacrolimus and Sirolimus in De Novo Renal Allograft Recipients. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 447-451.	1.0	20
202	Preoperative Mapping for Haemodialysis Access Surgery with CO2 Venography of the Upper Limb. <i>European Journal of Vascular and Endovascular Surgery</i> , 2010, 39, 340-345.	0.8	20
203	Renal Cell Carcinoma in the Allograft: What Is the Role of Polyomavirus. <i>Case Reports in Nephrology and Urology</i> , 2012, 2, 125-134.	1.5	20
204	Completeness and Satisfaction with the Education and Information Received by Patients Immediately after Kidney Transplant: A Mixed-Models Study. <i>Progress in Transplantation</i> , 2013, 23, 12-22.	0.4	20
205	A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CITED study. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 707-714.	0.4	20
206	Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2021, 73, e661-e671.	2.9	20
207	Clinical Utility of a New Enzymatic Assay for Determination of Mycophenolic Acid in Comparison With an Optimized LC-MS/MS Method. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 218-223.	1.0	19
208	Prevalence and determinants of anemia in the immediate postkidney transplant period. <i>Transplant International</i> , 2011, 24, 1208-1215.	0.8	19
209	Combined Kidney and Intestinal Transplantation in Patients With Enteric Hyperoxaluria Secondary to Short Bowel Syndrome. <i>American Journal of Transplantation</i> , 2013, 13, 1910-1914.	2.6	19
210	Genetic polymorphisms in <i>IL2</i> , <i>IL10</i> , <i>TGFβ1</i> , and <i>IL2</i> <i>RB</i> and acute rejection in renal transplant patients. <i>Clinical Transplantation</i> , 2014, 28, 649-655.	0.8	19
211	Occurrence of Diabetic Nephropathy After Renal Transplantation Despite Intensive Glycemic Control: An Observational Cohort Study. <i>Diabetes Care</i> , 2019, 42, 625-634.	4.3	19
212	Risk factors, histopathological features, and graft outcome of transplant glomerulopathy in the absence of donor-specific HLA antibodies. <i>Kidney International</i> , 2021, 100, 401-414.	2.6	19
213	Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 2050-2051.	0.4	18
214	role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. <i>Transplantation Proceedings</i> , 2002, 34, 1164-1170.	0.3	18
215	Secondary effects of immunosuppressive drugs after simultaneous pancreas-kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, ii33-ii39.	0.4	18
216	Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 759-761.	0.5	18

#	ARTICLE	IF	CITATIONS
217	A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1- α -hydroxymidazolam and 4-hydroxymidazolam in human plasma. <i>Biomedical Chromatography</i> , 2011, 25, 1091-1098.	0.8	18
218	Occupational Radiation Dose:Percutaneous Interventional Procedures on Hemodialysis Arteriovenous Fistulas and Grafts. <i>Radiology</i> , 2012, 264, 278-284.	3.6	18
219	Charcot neuroarthropathy after simultaneous pancreas-kidney transplantation: risk factors, prevalence, and outcome. <i>Clinical Transplantation</i> , 2015, 29, 712-719.	0.8	18
220	ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. <i>Transplant International</i> , 2017, 30, 83-95.	0.8	18
221	Monoclonal antibodies in renal transplantation: old and new. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 297-300.	0.4	17
222	Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 4044-4048.	0.4	17
223	Balancing Efficacy and Toxicity of Kidney Transplant Immunosuppression. <i>Transplantation Proceedings</i> , 2009, 41, 3393-3395.	0.3	17
224	Microscopic nephrocalcinosis in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 843-848.	0.4	17
225	<i>Mycobacterium genavense</i> infection in a solid organ recipient: a diagnostic and therapeutic challenge. <i>Transplant Infectious Disease</i> , 2016, 18, 125-131.	0.7	17
226	Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1507-1513.	1.7	17
227	Age-related changes in DNA methylation affect renal histology and post-transplant fibrosis. <i>Kidney International</i> , 2019, 96, 1195-1204.	2.6	17
228	How Delayed Graft Function Impacts Exposure to Mycophenolic Acid in Patients After Renal Transplantation. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 155-164.	1.0	17
229	Social Reinforcement and Remedial Instruction in the Elimination of a Classroom Behavior Problem. <i>Journal of Special Education</i> , 1968, 2, 291-305.	1.2	16
230	Secondary Renal Amyloidosis due to Long-Standing Tubulointerstitial Nephritis in a Patient With Sjögren Syndrome. <i>American Journal of Kidney Diseases</i> , 2005, 46, e75-e80.	2.1	16
231	Apparent Elevation of Cyclosporine Whole Blood Concentrations in a Renal Allograft Recipient. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 529-531.	1.0	16
232	Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype. <i>Pharmacogenomics Journal</i> , 2017, 17, 556-562.	0.9	16
233	Does kidney transplantation with a standard or expanded criteria donor improve patient survival? Results from a Belgian cohort. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 918-926.	0.4	16
234	Prophylaxis of cytomegalovirus infection in renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 3012-3016.	0.4	15

#	ARTICLE	IF	CITATIONS
235	THE EFFECT OF MYCOPHENOLATE MOFETIL ON HEPATITIS B VIRAL LOAD IN STABLE RENAL TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS B. <i>Transplantation</i> , 2001, 72, 1165-1166.	0.5	15
236	Circulating Donor-Specific Anti-HLA Antibodies Associate With Immune Activation Independent of Kidney Transplant Histopathological Findings. <i>Frontiers in Immunology</i> , 2022, 13, 818569.	2.2	15
237	Tailoring immunosuppressive therapy. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 2051-2054.	0.4	14
238	Immunosuppressive Drug Therapy and Subclinical Acute Renal Allograft Rejection: Impact and Effect. <i>Transplantation</i> , 2008, 85, S25-S30.	0.5	14
239	High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1515-1522.	0.4	14
240	Repeated kidney retransplantation—the Eurotransplant experience: a retrospective multicenter outcome analysis. <i>Transplant International</i> , 2020, 33, 617-631.	0.8	14
241	Impact of Vascular Calcification on Corrected QT Interval at the Time of Renal Transplantation. <i>American Journal of Nephrology</i> , 2012, 35, 24-30.	1.4	13
242	Postimplantation X-ray parameters predict functional catheter problems in peritoneal dialysis. <i>Kidney International</i> , 2014, 86, 1001-1006.	2.6	13
243	Pretransplant 4 β -hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2406-2415.	1.1	13
244	Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. <i>Kidney International Reports</i> , 2020, 5, 627-631.	0.4	13
245	Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. <i>Clinical Transplantation</i> , 2003, 17, 171-176.	0.8	12
246	Time to reach tacrolimus maximum blood concentration, mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients. <i>Clinical Therapeutics</i> , 2004, 26, 1834-1844.	1.1	12
247	Urinary Connective Tissue Growth Factor Is Associated with Human Renal Allograft Fibrogenesis. <i>Transplantation</i> , 2013, 96, 494-500.	0.5	12
248	Early Alteration of Kidney Function in Nonuremic Type 1 Diabetic Islet Transplant Recipients Under Tacrolimus-Mycophenolate Therapy. <i>Transplantation</i> , 2014, 98, 451-457.	0.5	12
249	Natural History of Bone Disease following Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 638-652.	3.0	12
250	Intracerebral haemorrhage caused by cefazoline-induced hypoprothrombinaemia in a renal transplant recipient. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 532-533.	0.4	11
251	Pseudoaneurysm Complicating Protocol Renal Transplant Biopsies: Case Reports. <i>Transplantation Proceedings</i> , 2008, 40, 1397-1398.	0.3	11
252	Troponin I Is a Predictor of Acute Cardiac Events in the Immediate Postoperative Renal Transplant Period. <i>Transplantation</i> , 2010, 89, 341-346.	0.5	11

#	ARTICLE	IF	CITATIONS
253	Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients. <i>Transplantation</i> , 2011, 92, 321-327.	0.5	11
254	Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 863-874.	1.1	11
255	Patterns of renal osteodystrophy 1â€%year after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2130-2139.	0.4	11
256	The evolution of histological changes suggestive of antibodyâ€mediated injury, in the presence and absence of donorâ€specific antiâ€HLA antibodies. <i>Transplant International</i> , 2021, 34, 1824-1836.	0.8	11
257	Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 2304-2308.	0.4	10
258	Immunosuppressive Drugs After Simultaneous Pancreas-Kidney Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 2840-2842.	0.3	10
259	Pharmacogenetic vs. Concentration-Controlled Optimization of Tacrolimus Dosing in Renal Allograft Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 595-596.	2.3	10
260	Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1965-1972.	0.4	10
261	Noncutaneous head and neck cancer in solid organ transplant patients: Single center experience. <i>Oral Oncology</i> , 2014, 50, 263-268.	0.8	10
262	Tubulointerstitial expression and urinary excretion of connective tissue growth factor 3 months after renal transplantation predict interstitial fibrosis and tubular atrophy at 5 years in a retrospective cohort analysis. <i>Transplant International</i> , 2017, 30, 695-705.	0.8	10
263	Fexofenadine, a Putative <i>In Vivo</i> Pâ€glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 989-996.	2.3	10
264	Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1901-1907.	1.4	10
265	Histological injury and renal transplant outcome: the cumulative damage hypothesis. <i>Transplantation Proceedings</i> , 2001, 33, 1149-1150.	0.3	9
266	C4d deposition in the peritubular capillaries of native renal biopsies. <i>Histopathology</i> , 2005, 47, 430-432.	1.6	9
267	The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003140.	3.9	9
268	Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation. <i>Scientific Reports</i> , 2021, 11, 15606.	1.6	9
269	Biological pathways and comparison with biopsy signals and cellular origin of peripheral blood transcriptomic profiles during kidney allograft pathology. <i>Kidney International</i> , 2022, 102, 183-195.	2.6	9
270	Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe. <i>Transplant International</i> , 0, 35, .	0.8	9

#	ARTICLE	IF	CITATIONS
271	A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 391-394.	1.3	8
272	Subacute cytomegalovirus appendicitis in a renal transplant recipient. <i>Transplant Infectious Disease</i> , 2013, 15, 96-97.	0.7	8
273	CHRONIC WOUNDS IN A KIDNEY TRANSPLANT RECIPIENT WITH MODERATE RENAL IMPAIRMENT. <i>Acta Clinica Belgica</i> , 2013, 68, 128-131.	0.5	8
274	Updated Manufacturer and European Medicines Agency Recommendations on the Use of Mycophenolate Acid. <i>Transplantation</i> , 2016, 100, e50-e51.	0.5	8
275	Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss. <i>Antiviral Research</i> , 2019, 168, 203-209.	1.9	8
276	Pre-transplant HLA Antibodies and Delayed Graft Function in the Current Era of Kidney Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 1886.	2.2	8
277	Post-transplant lymphoma of the pancreatic allograft in a kidney-pancreas transplant recipient: a misleading presentation. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3306-3310.	0.4	7
278	The Histological Picture of Indication Biopsies in the First 2 Weeks after Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1484-1493.	2.2	7
279	Static histomorphometry allows for a diagnosis of bone turnover in renal osteodystrophy in the absence of tetracycline labels. <i>Bone</i> , 2021, 152, 116066.	1.4	7
280	Kidney Transplantation After Rescue Allocation—the Eurotransplant Experience: A Retrospective Multicenter Outcome Analysis. <i>Transplantation</i> , 2022, 106, 1215-1226.	0.5	7
281	Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 884-889.	0.4	7
282	Heterologous versus homologous triple anti-COVID-19 vaccine regimens in patients on maintenance haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1384-1386.	0.4	7
283	The Pre-Transplant Non-HLA Antibody Burden Associates With the Development of Histology of Antibody-Mediated Rejection After Kidney Transplantation. <i>Frontiers in Immunology</i> , 2022, 13, 809059.	2.2	7
284	Forecasting of Patient-Specific Kidney Transplant Function With a Sequence-to-Sequence Deep Learning Model. <i>JAMA Network Open</i> , 2021, 4, e2141617.	2.8	7
285	Renal transplantation for end-stage renal disease due to paroxysmal nocturnal haemoglobinuria. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 3250-3252.	0.4	6
286	Clinical use of rapamycin in renal allograft recipients identifies its relevant toxicity profile and raises unsolved questions: a Single-Center experience. <i>Transplantation Proceedings</i> , 2003, 35, S138-S142.	0.3	6
287	Maintenance Immunosuppressive Agents as Risk Factors for BK Virus Nephropathy: The Need for True Drug Exposure Measurements. <i>Transplantation</i> , 2010, 89, 1296-1297.	0.5	6
288	Emerging Immunosuppressive Drugs in Kidney Transplantation. <i>Current Clinical Pharmacology</i> , 2011, 6, 130-136.	0.2	6

#	ARTICLE	IF	CITATIONS
289	Everolimus in acute kidney injury in a patient with breast cancer: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 386.	0.4	6
290	Replicative senescence and arteriosclerosis after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1984-1995.	0.4	6
291	Antibody-mediated rejection with and without donor-specific anti-human leucocyte antigen antibodies: performance of the peripheral blood 8-gene expression assay. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1328-1337.	0.4	6
292	Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation. <i>American Journal of Kidney Diseases</i> , 2022, 80, 718-729.e1.	2.1	6
293	Oral quinine pharmacokinetics and dietary salt intake. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 111-113.	0.8	5
294	Alemtuzumab induction therapy in kidney transplantation. <i>Lancet, The</i> , 2014, 384, 1649-1651.	6.3	5
295	Rhodococcus equi Sepsis in a Renal Transplant Recipient. <i>Transplantation Direct</i> , 2015, 1, 1-6.	0.8	5
296	Long-term, prolonged-release tacrolimus-based immunosuppression in de novo kidney transplant recipients: 5-year prospective follow-up of the ADHERE study patients. <i>Transplant International</i> , 2020, 33, 161-173.	0.8	5
297	A young patient with unexplained acute hepatorenal dysfunction. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1220-1222.	0.4	4
298	KIDNEY TRANSPLANTATION: CURRENT ISSUES AND FUTURE PROSPECTS. <i>Acta Clinica Belgica</i> , 2007, 62, 208-217.	0.5	4
299	Tacrolimus Formulations and African American Kidney Transplant Recipients: When Do Details Matter?. <i>American Journal of Kidney Diseases</i> , 2018, 71, 302-305.	2.1	4
300	What do we know about tacrolimus pharmacogenetics in transplant recipients? <i>Pharmacogenomics</i> , 2018, 19, 593-597.	0.6	4
301	In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 50-55.	1.2	4
302	The effect of IGL-1 preservation solution on outcome after kidney transplantation: A retrospective single-center analysis. <i>American Journal of Transplantation</i> , 2021, 21, 830-837.	2.6	4
303	Polyomavirus interstitial nephritis and concurrent post-transplant lymphoma in a renal allograft: coincidence or more?. <i>Transplant International</i> , 2005, 18, 1304-1307.	0.8	3
304	Artifactual hypocalcaemia after intravenous administration of gadodiamide (Omniscan®). <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1516-1517.	0.4	3
305	Therapeutic drug monitoring of mycophenolates: why make simple things complicated?. <i>Transplantation Reviews</i> , 2011, 25, 45-46.	1.2	3
306	The Bumpy Road of Genomic Medicine in Transplantation. <i>Transplantation</i> , 2012, 93, 578-579.	0.5	3

#	ARTICLE	IF	CITATIONS
307	Response to: "Bodyweight" adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance"™. British Journal of Clinical Pharmacology, 2017, 83, 1353-1356.	1.1	3
308	Kuypers and Vanhove reply to "Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?"™ by Neuhoﬀ and Tucker. British Journal of Clinical Pharmacology, 2018, 84, 1622-1623.	1.1	3
309	Delayed Bleeding of the Transplant Duodenum After Simultaneous Kidney-pancreas Transplantation: Case Series. Transplantation, 2020, 104, 184-189.	0.5	3
310	The effect of universal infant vaccination on the prevalence of hepatitis B immunity in adult solid organ transplant candidates. Journal of Viral Hepatitis, 2021, 28, 105-111.	1.0	3
311	Determination of tacrolimus, three mono-demethylated metabolites and a M1 tautomer in human whole blood by liquid chromatography " tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2021, 205, 114296.	1.4	3
312	POST-STREPTOCOCCAL GLOMERULONEPHRITIS: NOT AN EXTINCT DISEASE!. Acta Clinica Belgica, 2013, 68, 215-217.	0.5	2
313	Measures of Loop Diuretic Efficiency and Prognosis in Chronic Kidney Disease. CardioRenal Medicine, 2020, 10, 402-414.	0.7	2
314	Hyperhomocysteinemia: a trigger for complement-mediated TMA?. Acta Clinica Belgica, 2021, 76, 65-69.	0.5	2
315	Data and optimisation requirements for Kidney Exchange Programs. Health Informatics Journal, 2021, 27, 146045822110099.	1.1	2
316	Liver and/or Kidney Transplantation After SARS-CoV-2 Infection. Transplantation, 2021, Publish Ahead of Print, .	0.5	2
317	Letermovir exposure in transplant patients with end-stage renal disease on renal replacement therapy. Journal of Antimicrobial Chemotherapy, 2021, 76, 3322-3325.	1.3	2
318	Predicting model-informed precision dosing: A test case in tacrolimus dose adaptation for kidney transplant recipients. CPT: Pharmacometrics and Systems Pharmacology, 2022, , .	1.3	2
319	An uncommon tumor in a renal graft recipient: A diagnostic and therapeutic challenge. American Journal of Kidney Diseases, 2002, 40, e21.1-e21.6.	2.1	1
320	An unusual cause of ureteral obstruction in a renal allograft. Nephrology Dialysis Transplantation, 2006, 21, 3593-3594.	0.4	1
321	The Economic Burden of Post-Transplant Events in Renal Transplant Patients in Belgium (The PORTRAIT) Tj ETQq1 1,0,784314 rgBT /Ove	0,5	1
322	Sotrastaurin + Reduced-Exposure Tacrolimus Prevents Acute Rejection and Preserves Renal Function after De Novo Kidney Transplantation - 12 Month Results. Transplantation, 2012, 94, 980.	0.5	1
323	Response to "CYP3A5 Genotype, but Not CYP3A4*1b, CYP3A4*22, or Hematocrit, Predicts Tacrolimus Dose Requirements in Brazilian Renal Transplant Patients"™. Clinical Pharmacology and Therapeutics, 2013, 94, 202-203.	2.3	1
324	Response to "Pretransplantation Pharmacokinetic Assessments to Predict Posttransplantation Dosing Requirements in Renal Transplant Recipients: What Is Known?"™. Clinical Pharmacology and Therapeutics, 2013, 93, 307-308.	2.3	1

#	ARTICLE	IF	CITATIONS
325	Response to "Tacrolimus pharmacokinetics after kidney transplantation" Influence of changes in haematocrit and steroid dose™. British Journal of Clinical Pharmacology, 2015, 80, 1473-1474.	1.1	1
326	Predictive Modeling of Tacrolimus Dose Requirements: "All That Is Gold Does Not Glitter". American Journal of Transplantation, 2017, 17, 1144-1145.	2.6	1
327	Discrepancies between bioimpedance spectroscopy devices in haemodialysis patients. CKJ: Clinical Kidney Journal, 2020, 13, 906-908.	1.4	1
328	Acquired Perforating Disorders. , 2015, , 113-117.		1
329	Improve in-depth immunological risk assessment to optimize genetic-compatibility and clinical outcomes in child and adolescent recipients of parental donor kidney transplants: protocol for the INCEPTION study. BMC Nephrology, 2021, 22, 416.	0.8	1
330	Polyomavirus BK Genome Comparison Shows High Genetic Diversity in Kidney Transplant Recipients Three Months after Transplantation. Viruses, 2022, 14, 1533.	1.5	1
331	Dialysis Techniques in the Critic Ally-III Patient. Acta Clinica Belgica, 2000, 55, 237-243.	0.5	0
332	Kidney transplantation with rabbit antithymocyte globulin and sirolimus monotherapy. Lancet, The, 2003, 361, 969.	6.3	0
333	Acute kidney failure and an epigastric mass. CKJ: Clinical Kidney Journal, 2009, 2, 78-79.	1.4	0
334	Research Highlights. Pharmacogenomics, 2010, 11, 9-12.	0.6	0
335	Organ transplantation after cardiac death. Lancet, The, 2011, 377, 203.	6.3	0
336	Urinary Connective Tissue Growth Factor (CTGFu) as a Marker and Early Predictor of Chronic Renal Allograft Injury. Transplantation, 2012, 94, 82.	0.5	0
337	Recipients'¼ Smoking Habits and Death-Censored Renal Allograft Survival. Transplantation, 2012, 94, 24.	0.5	0
338	In Vivo CYP3A4-Activity, CYP3A5-Genotype and Hematocrit Predict Tacrolimus Dose-Requirements and Clearance in Renal Transplant Recipients. Transplantation, 2012, 94, 248-249.	0.5	0
339	Research Highlights: Highlights from the latest articles in transplantation pharmacogenomics. Pharmacogenomics, 2012, 13, 1679-1683.	0.6	0
340	Prof. Dr Yves Vanrenterghem. Nephrology Dialysis Transplantation, 2013, 28, 2919-2920.	0.4	0
341	Professor Dr Yves Vanrenterghem. Transplantation, 2014, 97, 125-126.	0.5	0
342	P882 COMBINED OR NOT COMBINED LIVER/KIDNEY TRANSPLANTATION FOR SYMPTOMATIC POLYCYSTIC LIVER DISEASE: SINGLE CENTER LONG-TERM OUTCOME EXPERIENCE. Journal of Hepatology, 2014, 60, S367-S368.	1.8	0

#	ARTICLE	IF	CITATIONS
343	SP691THE SOLUBLE UROKINASE RECEPTOR (SUPAR) PREDICTS MORTALITY IN END-STAGE RENAL DISEASE. Nephrology Dialysis Transplantation, 2015, 30, iii607-iii607.	0.4	0
344	P136 De novo HLA antibodies with similar specificities in three recipients from the same deceased organ donor. Human Immunology, 2016, 77, 137.	1.2	0
345	MO020ALITOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, CYTOPENIA AND POSTTRANSPLANT OUTCOMES: A RETROSPECTIVE ANALYSIS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
346	CAUSE OF DEATH AS A RISK FACTOR FOR IMMEDIATE AND LONG-TERM FUNCTIONAL OUTCOME OF RENAL ALLOGRAFTS FROM CADAVERIC DONORS. Transplantation, 1999, 67, S553.	0.5	0
347	Intrarenal arteriosclerosis and telomere attrition associate with dysregulation of the cholesterol pathway. Aging, 2020, 12, 7830-7847.	1.4	0
348	Title is missing!. , 2020, 17, e1003140.		0
349	Title is missing!. , 2020, 17, e1003140.		0
350	Title is missing!. , 2020, 17, e1003140.		0
351	Title is missing!. , 2020, 17, e1003140.		0
352	Title is missing!. , 2020, 17, e1003140.		0
353	Title is missing!. , 2020, 17, e1003140.		0
354	Infection-Related Nephropathies: Hepatitis C Virus. , 0, , 272-276.		0